Top Markets
#1 0G 0G +38.08%
#2 Axelar Axelar +22.24%
#3 Fake World Assets Fake World Assets +21.37%
#4 Bless Bless +19.68%
#5 Full Moon Full Moon +18.88%
#6 VVS Finance VVS Finance +18.18%
#7 Zora Zora +17.80%
#8 StonkBroker StonkBroker +16.79%
#9 Merlin's Seal BTC Merlin's Seal BTC +16.45%
#10 ADO Protocol ADO Protocol +15.64%
Coin of the day
0G 0G
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

3378
Classifica tra le azioni #13050
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and... Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of glioblastoma; and HX111, an ADC drug candidate to treat solid tumours. It is also developing proprietary in-house platforms, such as the VersatiBody, a multi-functional antibody discovery platform that generated two clinical-stage FIC bifunctional fusion proteins (HX009, HX044), as well as completed the preclinical development of multiple ADC/bispecific molecules, including FIC PPC HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC); and the autoRx40, an autoimmune therapeutic platform, completing the design of multiple candidate molecules in the field of autoimmune diseases, such as HX035, HX038, and HX138. Hanx Biopharmaceuticals (Wuhan) Co., Ltd. was incorporated in 2014 and is headquartered in Wuhan, China.
Prezzo delle azioni
$3.91
Capitalizzazione di mercato
$524.79M
Variazione (1 giorno)
-0.71%
Variazione (1 anno)
-
Paese
CN
Scambia Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)

Categoria

Healthcare
Storico del prezzo dell'azione per Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378)
Prezzo di chiusura più alto: $3.88 il 2026-08-01

Prezzo di chiusura più basso: $2.04 il 2025-12-01
Storico del prezzo dell'azione di Hanx Biopharmaceuticals (Wuhan) Co., Ltd. dal 2025 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) 56.13%
2025 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.01 -13.08%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $752.76 6.28%
CH